Sertraline for Hot Flash Management
Efficacy and Safety
- In patients taking tamoxifen, sertraline 50 mg daily is superior to placebo in reducing hot flashes, according to the National Comprehensive Cancer Network 1
- Sertraline has weak or no effects on CYP2D6 enzyme, making it preferable to paroxetine or fluoxetine in tamoxifen users, as recommended by the National Comprehensive Cancer Network 1
- Citalopram and venlafaxine also have minimal CYP2D6 effects and may be better therapeutic alternatives in tamoxifen users, as suggested by the Journal of the National Comprehensive Cancer Network 1, 2
- If fezolinetant is unavailable, venlafaxine (75 mg) or gabapentin (900 mg) are more effective alternatives than sertraline, with venlafaxine showing 61% reduction and gabapentin showing 46% reduction in hot flash severity, according to the National Comprehensive Cancer Network 1, 3
Discontinuation and Dosing
- Sertraline must be tapered gradually on discontinuation to prevent withdrawal symptoms, as recommended by the National Comprehensive Cancer Network 4
- The optimal dose is 50 mg daily based on available evidence in tamoxifen users, according to the National Comprehensive Cancer Network 1
Sertraline for Hot Flash Treatment
Efficacy and Recommendations
- The American College of Obstetricians and Gynecologists and North American Menopause Society are not cited here, however, sertraline (50-100 mg daily) reduces hot flashes in menopausal women, though with mixed results and substantial individual variability 5
- In tamoxifen users specifically, sertraline 50 mg was superior to placebo in reducing hot flashes, though it did not affect quality of life measures 5
- Sertraline has weak or no effects on CYP2D6, making it preferable to paroxetine or fluoxetine in breast cancer patients taking tamoxifen 5
- The optimal dose appears to be 50 mg daily based on the available evidence 5
- Sertraline should be stopped gradually to prevent discontinuation symptoms 5
- Given the substantial placebo response and individual variability, a trial period is warranted to assess individual response 5